Weight loss · Las Vegas area, NV
Weight loss and obesity studies in Las Vegas area, NV
15 recruiting studies have a site in the Las Vegas area. This page includes nearby cities such as Henderson, North Las Vegas, Paradise, Summerlin.
15 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Las Vegas, NV + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Las Vegas, NV + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Las Vegas, NV + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Las Vegas, NV + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Las Vegas, NV + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Las Vegas, NV + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Las Vegas, NV + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Las Vegas, NV + 42 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- Las Vegas, NV + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Las Vegas, NV + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
- Location
- Las Vegas, NV + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
- Location
- Las Vegas, NV + 40 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Novo Nordisk A/S
- Location
- Las Vegas, NV + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S
- Location
- Las Vegas, NV + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Corxel Pharmaceuticals
- Location
- Las Vegas, NV + 1 other US site
- Eligibility basics
- Ages 18–55 · Women only
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.